OncoMatch/Clinical Trials/NCT06793813
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
Is NCT06793813 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies cadonilimab，bevacizumab，docetaxel for stage ivb lung cancer.
Treatment: cadonilimab，bevacizumab，docetaxel — This phase II trial studies how well cadonilimab combined with Bevacizumab and docetaxel work in treating patients with non-squamous and stage IV non-small cell lung cancer. Cadonilimab, a PD-1/CTLA-4 bispecific antibody, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab can regulate tumor microenvironment. Docetaxel was used in standard of care chemotherapy for non-small cell lung cancer, work to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cadonilimab, bevacizumab and docetaxel together may work better in treating patients with non-squamous non-small lung cancer compared to standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Patients must not have EGFR sensitizing mutations
Required: EGFR T790M
Patients must not have EGFR T790M mutation
Required: ALK fusion
Patients must not have ... ALK gene fusion
Required: ROS1 rearrangement
Patients must not have ... ROS 1 gene rearrangement
Required: BRAF V600E
Patients must not have ... BRAF V600E mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
Patients must have progressed on at most a PD-1/L1 inhibitor and a platinum-based chemotherapy (combined or sequential, regardless of sequence), and at least two cycles of PD-1/L1 inhibitor (combined or non-combined chemotherapy) with clinical benefits (PFS ≥ 3 months)
Must have received: anti-PD-L1 therapy
Patients must have progressed on at most a PD-1/L1 inhibitor and a platinum-based chemotherapy (combined or sequential, regardless of sequence), and at least two cycles of PD-1/L1 inhibitor (combined or non-combined chemotherapy) with clinical benefits (PFS ≥ 3 months)
Must have received: platinum-based chemotherapy
Patients must have progressed on at most a PD-1/L1 inhibitor and a platinum-based chemotherapy (combined or sequential, regardless of sequence), and at least two cycles of PD-1/L1 inhibitor (combined or non-combined chemotherapy) with clinical benefits (PFS ≥ 3 months)
Cannot have received: CTLA-4 inhibitor
Previously received treatment for tumor immune mechanism other than any anti-PD-1/L1 inhibitor for advanced NSCLC stage, such as CTLA-4（CD152）
Cannot have received: TIGIT inhibitor
such as ... TIGIT
Cannot have received: OX-40 inhibitor
such as ... OX-40
Cannot have received: CD137 inhibitor
such as ... CD137
Cannot have received: ICOS inhibitor
such as ... ICOS
Cannot have received: CD40 inhibitor
such as ... CD40
Cannot have received: CD47 inhibitor
such as ... CD47
Cannot have received: CD73 inhibitor
such as ... CD73
Cannot have received: GITR inhibitor
such as ... GITR
Cannot have received: TOX inhibitor
such as ... TOX
Cannot have received: LAG-3 inhibitor
such as ... LAG-3
Cannot have received: TIM3 inhibitor
such as ... TIM3
Cannot have received: SIRPA inhibitor
such as ... SIRPα
Cannot have received: BTLA inhibitor
such as ... BTLA（CD272）
Cannot have received: VISTA inhibitor
such as ... VISTA（B7-H5）
Cannot have received: LIGHT inhibitor
such as ... LIGHT（CD258）
Cannot have received: B7-H3 inhibitor
such as ... B7-H3（CD276）
Cannot have received: B7-H4 inhibitor
such as ... B7-H4（VTCN1）
Cannot have received: HVEM inhibitor
such as ... HVEM
Cannot have received: CD80/CD86 inhibitor
such as ... CD80/CD86
Cannot have received: MHC II inhibitor
such as ... MHC Ⅱ
Cannot have received: GAL9 inhibitor
such as ... GAL9
Cannot have received: IDO inhibitor
such as ... IDO
Cannot have received: PVR inhibitor
such as ... PVR（CD155）
Cannot have received: Nectin-2 inhibitor
such as ... Nectin-2（CD112）
Cannot have received: taxane (docetaxel)
Patients have prior exposure to docetaxel
Cannot have received: anti-VEGF therapy (bevacizumab)
Patients have prior exposure to ... bevacizumab
Lab requirements
Blood counts
ANC ≥ 1500/uL; Platelets ≥ 100,000/uL; Hemoglobin ≥ 9.0 g/dL
Kidney function
Creatinine clearance (CrCl) ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN; AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN for participants with liver metastases); Serum albumin ≥ 28 g/L
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
ANC ≥ 1500/uL; Platelets ≥ 100,000/uL; Hemoglobin ≥ 9.0 g/dL; Creatinine clearance (CrCl) ≥ 50 mL/min; Total bilirubin ≤ 1.5 x ULN; AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN for participants with liver metastases); Serum albumin ≥ 28 g/L; LVEF ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify